Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung

Japanese Journal of Clinical Oncology

Volumn 37, Issue 7, 2007, Pages 482-486

  Fujiwara, Yutaka ^a   Sekine, Ikuo ^a   Tsuta, Koji ^a   Ohe, Yuichiro ^a   Kunitoh, Hideo ^a   Yamamoto, Noboru ^a   Nokihara, Hiroshi ^a   Yamada, Kazuhiko ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Irinotecan; Large cell neuroendocrine carcinoma; Lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CANCER; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; TAXOIDS; VINBLASTINE;

EID: 34548344037     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym053     Document Type: Article

References (26)

1. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB, Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural immunohistochemical and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-53.
2. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. World Health Organization International Histological Classication of Tumors. Histological typing of lung and pleural tumors, 3rd edn. Berlin: Springer-Verlag 1999.
3. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996;62:798-809.
4. Dresler CM, Ritter JH, Patterson GA, Ross E, Bailey MS, Wick MR. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 1997;63: 180-5.
5. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-44.
6. Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124: 285-92.
7. Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: A prognostic spectrum. J Clin Oncol 2006;24:70-6.
8. Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005;49:217-23.
9. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
10. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-31.
11. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-41.
12. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
13. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-61.
14. Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JA, et al. Gemcitabine plus carboplatin versus mitomycin ifosfamide and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: A phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005;23:142-53.
15. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, 5th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between 'small cells' and 'large cells' in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001;116:466-72.
19. Kakinuma H, Mikami T, Iwabuchi K, Yokoyama M, Hattori M, Ohno E, et al. Diagnostic findings of bronchial brush cytology for pulmonary large cell neuroendocrine carcinomas: Comparison with poorly differentiated adenocarcinomas, squamous cell carcinomas, and small cell carcinomas. Cancer 2003;99:247-54.
20. Hiroshima K, Abe S, Ebihara Y, Ogura S, Kikui M, Kodama T, et al. Cytological characteristics of pulmonary large cell neuroendocrine carcinoma. Lung Cancer 2005;48:331-7.
21. Marmor S, Koren R, Halpern M, Herbert M, Rath-Wolfson L. Transthoracic needle biopsy in the diagnosis of large-cell neuroendocrine carcinoma of the lung. Diagn Cytopathol 2005;33: 238-43.
22. Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR alpha, PDGFR beta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005;23:8774-85.
23. Kozuki T, Fujimoto N, Ueoka H, Kiura K, Fujiwara K, Shiomi K, et al. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol 2005;131:147-51.
24. Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005;129:977-83.
25. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based aduvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
26. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.